| HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025 |
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., April 24, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED including savolitinib, fruquintinib and surufatinib, which will be presented at the upcoming American Association of Cancer Research (AACR) Annual Meeting 2025, taking place on April 25-30, 2025 in Chicago, Illinois. |
globenewswire.com |
2025-04-24 00:00:00 |
Czytaj oryginał (ang.) |
| HUTCHMED shares rise 10% as Phase II gastric cancer trial hits key milestone |
Shares in Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013) rose 10% in early trading on Tuesday after the biopharma company announced it had completed patient enrolment for a key phase II trial of its cancer drug savolitinib in China. The study is testing the treatment in people with gastric or gastroesophageal junction cancer whose tumours show MET gene amplification - a relatively rare but aggressive subtype. |
proactiveinvestors.co.uk |
2025-04-22 08:12:57 |
Czytaj oryginał (ang.) |
| HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China |
HONG KONG and FLORHAM PARK, N.J., April 22, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has completed enrollment of the registration phase of its Phase II trial of savolitinib in gastric cancer patients with MET amplification. |
globenewswire.com |
2025-04-22 00:00:00 |
Czytaj oryginał (ang.) |
| Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial |
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Camzyos--Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial. |
businesswire.com |
2025-04-14 20:15:00 |
Czytaj oryginał (ang.) |
| 3 Internet Delivery Services Stocks in Focus Amid Industry Challenges |
Tariff war, inflationary pressure and still-high interest rates are major concerns for the Zacks Internet - Delivery Services industry. However, efforts to adopt consumer preferences and technological advancements are likely to help GDDY, QNST and ASUR navigate the headwinds. |
zacks.com |
2025-04-08 15:00:39 |
Czytaj oryginał (ang.) |
| Edgewise Therapeutics Sees Meaningful HCM Treatment Gains With EDG-7500 In Phase 2 Study |
Edgewise Therapeutics, Inc., EWTX on Wednesday reported topline data of EDG-7500 from the Phase 2 CIRRUS-HCM four-week trial in participants with obstructive or nonobstructive Hypertrophic Cardiomyopathy (HCM). |
benzinga.com |
2025-04-02 16:27:12 |
Czytaj oryginał (ang.) |
| Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) |
– Phase 2 trial of EDG-7500 demonstrated rapid and clinically meaningful reductions in LVOT gradients in participants with obstructive HCM – – Four-week treatment with EDG-7500 demonstrated substantial improvements in measures of feel and function, reductions in key cardiac biomarkers and positive trends in measures of diastolic function – – EDG-7500 was generally well-tolerated; clinical activity was observed without meaningful changes in LVEF, including no participant with a value below 50% – BOULDER, Colo. , April 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced positive top-line data of EDG-7500 from the Phase 2 CIRRUS-HCM four-week trial in participants with obstructive or nonobstructive HCM. |
prnewswire.com |
2025-04-02 10:00:00 |
Czytaj oryginał (ang.) |
| Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Results from Phase 2 CIRRUS-HCM 28-Day Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) on Wednesday, April 2 at 8:30 am Eastern Time |
BOULDER, Colo. , March 26, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that members of the management team will hold a live webcast to discuss top-line data of EDG-7500 from the Phase 2 CIRRUS-HCM 28-day trial in patients with obstructive or nonobstructive HCM on Wednesday, April 2, 2025, at 8:30 am ET. |
prnewswire.com |
2025-03-26 18:45:00 |
Czytaj oryginał (ang.) |
| Terrestrial Energy to Become First Publicly Traded Molten Salt Nuclear Reactor Developer Through Combination with HCM II Acquisition Corp. |
CHARLOTTE, N.C. and STAMFORD, Conn., March 26, 2025 (GLOBE NEWSWIRE) -- Terrestrial Energy Inc., a developer of small modular nuclear power plants using advanced reactor technology, and HCM II Acquisition Corp. (Nasdaq: HOND), today announced an agreement for a business combination (the “Transaction” or the “Business Combination”) that will result in Terrestrial Energy becoming a public company to be listed on Nasdaq under the ticker symbol “IMSR”. |
globenewswire.com |
2025-03-26 11:30:00 |
Czytaj oryginał (ang.) |
| AI Becoming Essential to HCM, ISG Says |
STAMFORD, Conn.--(BUSINESS WIRE)---- $III #AI--AI is becoming central to HCM and employee engagement, with two-thirds of enterprises expected to need AI-enabled capabilities by 2027, ISG says. |
businesswire.com |
2025-03-21 11:48:00 |
Czytaj oryginał (ang.) |
| HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma |
— First and only EZH2 inhibitor approved by the NMPA — — HUTCHMED's fourth product, and its first approval in hematological malignancies — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 21, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (“NDA”) for TAZVERIK® (tazemetostat) has been granted conditional approval in China for the treatment of adult patients with relapsed or refractory (“R/R”) follicular lymphoma (“FL”) with EZH2 mutation who have received at least two prior systemic therapies. |
globenewswire.com |
2025-03-21 08:00:00 |
Czytaj oryginał (ang.) |
| Intended Retirement of Independent Non-executive Directors and changes of composition of board committees |
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 20, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces that Mr Paul Rutherford Carter and Mr Graeme Allan Jack, who have both served as Independent Non-executive Directors of the Company for more than eight years, have informed the Company that they would not seek re-election after retiring from the Board at the forthcoming annual general meeting of the Company to be held on May 13, 2025 (“AGM”). |
globenewswire.com |
2025-03-20 07:30:00 |
Czytaj oryginał (ang.) |
| US pharma restrictions won't affect Hutchmed operations, says CEO |
Weiguo Su, CEO of Chinese pharma company HUTCHMED, talks about the company's latest earnings report, and why it's positioned to be 'sustainably profitable' from this point despite some external challenges. |
youtube.com |
2025-03-20 02:46:53 |
Czytaj oryginał (ang.) |
| HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025 |
— SAVANNAH Phase II trial demonstrated high and durable response rates with savolitinib plus TAGRISSO ® in MET-high lung cancer, representing a promising chemo-free oral treatment strategy to address mechanisms of resistance in the advanced setting — |
globenewswire.com |
2025-03-19 22:00:00 |
Czytaj oryginał (ang.) |
| HUTCHMED (China) Limited (HCM) Q4 2024 Earnings Call Transcript |
HUTCHMED (China) Limited (NASDAQ:HCM ) Q4 2024 Earnings Conference Call March 19, 2025 8:00 AM ET Company Participants David Ng - Head:IR Wei-Guo Su - CEO & Chief Scientific Officer Johnny Cheng - CFO George Yuan - Head of Commercial Michael Shi - EVP, Head of R&D & Chief Medical Officer Conference Call Participants Clara Dong - Jefferies Alec Stranahan - Bank of America Julie Simmonds - Panmure Liberum Adam McCarter - Cavendish Chen Chen - UBS Cindy Chai - HSBC David Ng Welcome, everyone. Thank you for joining HUTCHMED 2024 Full Year Results Call. |
seekingalpha.com |
2025-03-19 14:17:59 |
Czytaj oryginał (ang.) |
| Hutchmed's Oncology Revenue Hits $271.5 Million, Rising 65% On Fruzaqla Strength |
On Wednesday, Hutchmed (China) Limited (NASDAQ: HCM) reported 2024 earnings of 22 cents per ADS or 4 cents per share, down 59 cents or 12 cents a year ago. Sales fell 25% year over year to $630.20 million. |
benzinga.com |
2025-03-19 14:09:45 |
Czytaj oryginał (ang.) |
| HUTCHMED Reports 2024 Full Year Results and Provides Business Updates |
65% oncology products revenue growth drove profitable operation and supported new ATTC platform 65% oncology products revenue growth drove profitable operation and supported new ATTC platform |
globenewswire.com |
2025-03-19 09:00:00 |
Czytaj oryginał (ang.) |
| Innovent and HUTCHMED Jointly Announce that the FRUSICA-2 Phase 2/3 Study of Sintilimab and Fruquintinib Combination Has Met Its Primary Endpoint in Advanced Renal Cell Carcinoma in China |
SAN FRANCISCO and SUZHOU, China , March 18, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, and HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13), today jointly announce that the FRUSICA-2 Phase 2/3 clinical trial evaluating sintilimab in combination with fruquintinib as second-line treatment for locally advanced or metastatic renal cell carcinoma (RCC) in China has met its primary endpoint of progression free survival (PFS) per RECIST 1.1 as assessed by blinded independent central review (BICR). The combination of sintilimab and fruquintinib received conditional approval from China's National Medical Products Administration (NMPA) for the treatment of patients with advanced endometrial cancer with Mismatch Repair proficient (pMMR) tumors that have failed prior systemic therapy and are not candidates for curative surgery or radiation, based on data from the FRUSICA-1 study (NCT03903705). |
prnewswire.com |
2025-03-18 22:55:00 |
Czytaj oryginał (ang.) |
| HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China |
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) and Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), today jointly announce that the FRUSICA-2 Phase II/III clinical trial evaluating fruquintinib in combination with sintilimab as second-line treatment for locally advanced or metastatic renal cell carcinoma (“RCC”) in China has met its primary endpoint of progression free survival (“PFS”) per RECIST 1.1 as assessed by blinded independent central review (BICR). |
globenewswire.com |
2025-03-18 22:00:00 |
Czytaj oryginał (ang.) |
| Gallagher Certified as Smartchoice® Preferred Provider by Brandon Hall Group |
Brandon Hall Group, the leader in Empowering, Recognizing and Certifying Excellence in HCM recently announced that Gallagher is certified as a Smartchoice® Preferred Solution Provider. Confirming that Gallagher delivers sales, leadership, and organizational consulting solutions that improve clients' business results. Brandon Hall Group, the leader in Empowering, Recognizing and Certifying Excellence in HCM recently announced that Gallagher is certified as a Smartchoice® Preferred Solution Provider. Confirming that Gallagher delivers sales, leadership, and organizational consulting solutions that improve clients' business results. |
globenewswire.com |
2025-03-10 15:41:00 |
Czytaj oryginał (ang.) |
| HUTCHMED (HCM) Upgraded to Buy: Here's Why |
HUTCHMED (HCM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2025-02-20 15:00:30 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Believe HUTCHMED (HCM) Could Rally 72.83%: Here's is How to Trade |
The average of price targets set by Wall Street analysts indicates a potential upside of 72.8% in HUTCHMED (HCM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2025-02-20 12:55:27 |
Czytaj oryginał (ang.) |
| HUTCHMED to Announce 2024 Final Results |
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2024 on Wednesday, March 19, 2025 at 7:00 am Eastern Daylight Time (EDT) / 11:00 am Greenwich Mean Time (GMT) / 7:00 pm Hong Kong Time (HKT). |
globenewswire.com |
2025-02-19 05:30:00 |
Czytaj oryginał (ang.) |
| Advanced Human Capital Management (HCM) Solution Now Available to Convenience Retail and Wholesale Petroleum Operators as PDI Technologies Announces Entry into Embedded Partner Program with Paycor |
All-in-one solution fully integrates with PDI Enterprise to simplify workforce management and optimize productivity ATLANTA , Jan. 22, 2025 /PRNewswire/ -- Convenience retail and wholesale petroleum operators face increasing demands with labor management, prompting the need for more efficient solutions to streamline workforce planning, processes, and execution. After an extensive assessment of leading solutions that would best fit the complex needs of the industry, PDI Technologies has announced entry into the embedded partner program with Paycor HCM, Inc. (Nasdaq: PYCR) to integrate Paycor's comprehensive human capital management (HCM) solution into PDI Enterprise. |
prnewswire.com |
2025-01-22 13:00:00 |
Czytaj oryginał (ang.) |
| HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC |
— Indication expands to include treatment-naïve patients — — The 2021 conditional approval in previously treated patients converted to full approval — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 14, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the supplemental New Drug Application for ORPATHYS® (savolitinib) has been granted approval by the China National Medical Products Administration (“NMPA”) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (“NSCLC”) with MET exon 14 skipping alteration. |
globenewswire.com |
2025-01-14 01:00:00 |
Czytaj oryginał (ang.) |
| $HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Paycor HCM, Inc. - PYCR |
NEW YORK , Jan. 7, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Paycor HCM, Inc. (NYSE: PYCR ), relating to the proposed merger with Paychex. |
prnewswire.com |
2025-01-07 21:00:00 |
Czytaj oryginał (ang.) |
| Jay Whitehead Joins Asure as Senior Vice President of AsurePay(TM) and Marketplace |
Seasoned executive, entrepreneur, and HCM thought leader to drive innovation and foster strategy partnerships at fast-growing payroll provider Seasoned executive, entrepreneur, and HCM thought leader to drive innovation and foster strategy partnerships at fast-growing payroll provider |
globenewswire.com |
2025-01-07 16:46:00 |
Czytaj oryginał (ang.) |
| Apax Funds to Sell Their Majority Stake in Paycor HCM, Inc. to Paychex, Inc. |
NEW YORK , Jan. 7, 2025 /PRNewswire/ -- Apax Partners LLP ("Apax") today announced that Paycor HCM, Inc. (Nasdaq: PYCR) ("Paycor"), a leading provider of human capital management ("HCM") software, has entered into a definitive agreement with Paychex, Inc. (Nasdaq: PAYX) ("Paychex") to be acquired in an all-cash transaction for $22.50 per share, representing a total enterprise value of $4.1 billion. Funds advised by Apax, together with certain of their affiliates, currently own a majority of Paycor's outstanding common stock. |
prnewswire.com |
2025-01-07 11:48:00 |
Czytaj oryginał (ang.) |
| Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million |
On Wednesday, Hutchmed (China) Limited HCM entered into two agreements to divest its 45% equity interest in Shanghai Hutchison Pharmaceuticals Limited (SHPL) for approximately $608 million (RMB 4.478 billion) in cash to GP Health Service Capital Co., Ltd and Shanghai Pharmaceuticals Holding Co., Ltd. |
benzinga.com |
2025-01-02 09:38:54 |
Czytaj oryginał (ang.) |
| HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy |
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (“NDA”) for the combination of ORPATHYS® (savolitinib) and TAGRISSO® (osimertinib) for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor (“EGFR”) mutation-positive non-small cell lung cancer (“NSCLC”) with MET amplification after disease progression on first-line EGFR inhibitor therapy has been accepted and granted priority review by the China National Medical Products Administration (“NMPA”). ORPATHYS® is an oral, potent and highly selective MET tyrosine kinase inhibitor (“TKI”). TAGRISSO® is a third-generation, irreversible EGFR TKI. This acceptance also triggers a milestone payment from AstraZeneca. |
globenewswire.com |
2025-01-01 21:00:00 |
Czytaj oryginał (ang.) |
| Billionaire Li Ka-shing's Hutchmed in $608 mln health unit stake sales |
Hutchmed (China), controlled by tycoon Li Ka-shing, is selling stakes in its health subsidiary for around $608 million as the billionaire and his flagship conglomerate look to ramp up capital and pivot towards core operations at the drugmaker. |
reuters.com |
2025-01-01 17:42:32 |
Czytaj oryginał (ang.) |
| HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture |
— HUTCHMED continues to deliver on its strategy outlined in November 2022 to create value, prioritize its portfolio and bring innovative medicines to patients globally — |
globenewswire.com |
2025-01-01 07:46:00 |
Czytaj oryginał (ang.) |
| Paycor HCM Shareholders are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses |
SAN DIEGO, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating whether Paycor HCM, Inc. (NASDAQ: PYCR), any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose material adverse to investors. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws. |
globenewswire.com |
2024-12-30 12:05:00 |
Czytaj oryginał (ang.) |
| Paycor HCM: Positive On The Mid-Term Growth Outlook (Rating Upgrade) |
I am upgrading PYCR to a buy rating due to optimistic mid-term guidance and strong earnings growth potential. PYCR's new guidance indicates sustainable mid-teens recurring revenue growth and >800 bps adj EBIT margin expansion, driving >20% adj EBIT growth. Successful upmarket traction, increased sales headcount, and strong broker relationships are key drivers of PYCR's positive outlook. |
seekingalpha.com |
2024-12-25 03:29:09 |
Czytaj oryginał (ang.) |
| Paycor HCM Shareholders are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses |
SAN DIEGO, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating whether Paycor HCM, Inc. (NASDAQ: PYCR), any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose material adverse to investors. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws. |
globenewswire.com |
2024-12-23 11:38:00 |
Czytaj oryginał (ang.) |
| Paycor HCM Shareholders are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses |
SAN DIEGO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating whether Paycor HCM, Inc. (NASDAQ: PYCR), any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose material adverse to investors. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws. |
globenewswire.com |
2024-12-19 11:55:00 |
Czytaj oryginał (ang.) |
| Robbins LLP Informs Paycor HCM, Inc. Stockholders that it is Investigating the Officers and Directors of PYCR to Determine if They Breached Fiduciary Duties Owed to Shareholders |
SAN DIEGO, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP is investigating Paycor HCM, Inc. (NASDAQ: PYCR) to determine whether certain Paycor officers and directors violated securities laws and breached fiduciary duties to shareholders. Paycor HCM, together with its subsidiaries, engages in the provision of human capital management solutions for small and medium-sized businesses primarily in the United States. |
globenewswire.com |
2024-12-13 17:52:00 |
Czytaj oryginał (ang.) |
| HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib) |
— US$10 million milestone payment to HUTCHMED follows first national reimbursement in Europe — — Follows June 2024 European approval of FRUZAQLA ® (fruquintinib), the first novel oral targeted therapy in the EU for metastatic colorectal cancer regardless of biomarker status in over a decade — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 12, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it will receive a US$10 million milestone payment by its partner Takeda (TSE:4502/NYSE:TAK). |
globenewswire.com |
2024-12-12 21:00:00 |
Czytaj oryginał (ang.) |
| HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy |
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the Center for Drug Evaluation of China's National Medical Products Administration (“NMPA”) has granted Breakthrough Therapy Designation (“BTD”) to the combination of ORPATHYS® (savolitinib) and TAGRISSO® (osimertinib) for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor (“EGFR”) mutation‑positive non‑small cell lung cancer (“NSCLC”) with MET amplification after disease progression on EGFR inhibitor therapy. ORPATHYS® is an oral, potent and highly selective MET tyrosine kinase inhibitor (“TKI”). TAGRISSO® is a third-generation, irreversible EGFR TKI. |
globenewswire.com |
2024-12-12 01:00:00 |
Czytaj oryginał (ang.) |
| Paycor HCM Shareholders are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses |
SAN DIEGO, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating whether Paycor HCM, Inc. (NASDAQ: PYCR), any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose material adverse to investors. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws. |
globenewswire.com |
2024-12-05 13:45:00 |
Czytaj oryginał (ang.) |
| Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer |
SAN FRANCISCO, U.S. and SUZHOU, China , Dec. 3, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, and HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13)，jointly announce that the New Drug Application (NDA) for the combination of TYVYT® (sintilimab injection) and ELUNATE® (fruquintinib) has been granted conditional approval in China for the treatment of patients with advanced endometrial cancer with Mismatch Repair proficient (pMMR) tumors that have failed prior systemic therapy and are not candidates for curative surgery or radiation. This approval follows the priority review status and breakthrough therapy designation by the National Medical Products Administration (NMPA) of China and marks the eighth approved indication for TYVYT® (sintilimab injection). |
prnewswire.com |
2024-12-03 21:00:00 |
Czytaj oryginał (ang.) |
| HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer |
— First regulatory approval for fruquintinib combination therapy with an immune checkpoint inhibitor — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) and Innovent Biologics, Inc. (“Innovent”) (HKEX:1801) today jointly announce that the New Drug Application (“NDA”) for the combination of ELUNATE® (fruquintinib) and TYVYT® (sintilimab injection) has been granted conditional approval in China for the treatment of patients with advanced endometrial cancer with Mismatch Repair proficient (“pMMR”) tumors that have failed prior systemic therapy and are not candidates for curative surgery or radiation. |
globenewswire.com |
2024-12-03 07:00:00 |
Czytaj oryginał (ang.) |
| HUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current Terms |
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 28, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that following the contract renewal with the China National Healthcare Security Administration (“NHSA”), the updated National Reimbursement Drug List (“NRDL”) effective on January 1, 2025 will continue to include ORPATHYS® (savolitinib) at the same terms as the current two-year agreement. |
globenewswire.com |
2024-11-28 07:30:00 |
Czytaj oryginał (ang.) |
| HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan |
— Launch follows approval by Japanese Ministry of Health, Labour and Welfare in September 2024 — — Milestone payment to be made to HUTCHMED from Takeda — — Fruquintinib already launched in several regions including the United States, Europe and China — HONG KONG, SHANGHAI & FLORHAM PARK, N.J., Nov. 21, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it will receive a milestone payment following the pricing approval and launch of FRUZAQLA® (fruquintinib) 1mg/5mg capsules in Japan by its partner Takeda (TSE:4502/NYSE:TAK) for patients with previously treated metastatic colorectal cancer (“CRC”). |
globenewswire.com |
2024-11-22 01:30:00 |
Czytaj oryginał (ang.) |
| Paycor HCM Shareholders are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses |
SAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating whether Paycor HCM, Inc. (NASDAQ: PYCR), any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose material adverse to investors. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws. |
globenewswire.com |
2024-11-20 16:51:00 |
Czytaj oryginał (ang.) |
| HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee |
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces that Dr Chaohong Hu (Dr Mary Hu) is appointed as an Independent Non-executive Director and a member of the Technical Committee of the Company with effect from November 21, 2024. |
globenewswire.com |
2024-11-20 06:30:00 |
Czytaj oryginał (ang.) |
| Paycor HCM Shareholders are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses |
SAN DIEGO, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating whether Paycor HCM, Inc. (NASDAQ: PYCR), any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose material adverse to investors. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws. |
globenewswire.com |
2024-11-08 11:09:00 |
Czytaj oryginał (ang.) |
| HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress |
HONG KONG, SHANGHAI, and FLORHAM PARK, N.J., Nov. 05, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from the sovleplenib ESLIM-01 Phase III trial, as well as several investigator-initiated studies of compounds discovered by HUTCHMED will be presented at the American Society of Hematology (“ASH”) Annual Meeting taking place on December 7-10, 2024 in San Diego, USA, and the European Society for Medical Oncology (“ESMO”) Asia Congress 2024, taking place on December 6-8, 2024 in Singapore. |
globenewswire.com |
2024-11-06 01:00:00 |
Czytaj oryginał (ang.) |